Sort
4,870 grants matching “glp 1”
Development of an Oral Pill to Mimic the Effects of Gastric Bypass Surgery
$916,400Vasu Sethuraman · Syntis Bio Inc · R44 · FY2025 · DK
Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers
$916,147Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Novel antioxidants for periodontal disease
$916,102Inotek Pharmaceuticals Corporation · R44 · FY2004 · DE
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides
$915,110Jian Li · Monash University · R01 · FY2012 · AI
Structural Analysis Of Candidate Genes For Type 2 Diabetes and Obesity
$914,965Leslie J Baier · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
Long Acting Native GLP-1 formulations for Type 1 Diabetes
$914,882Elijah M Bolotin · Pharmain Corporation · R44 · FY2007 · DK
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection
$913,769Gary Fanger · Rise Therapeutics, Llc · R44 · FY2021 · AI
Safe and effective anti CD154 antibodies for therapeutic intervention
$912,191Jay L Rothstein · Immunext, Inc. · R44 · FY2017 · AI
Safe and effective anti CD154 antibodies for therapeutic intervention
$912,191Jay L Rothstein · Immunext, Inc. · R44 · FY2016 · AI
Treatment of Canine Diabetic Cataracts
$911,085Milton None Wyman · Therapeutic Vision, Inc. · R44 · FY2011 · EY
Topical Eyedrop Therapy for Keratoconus
$909,474Sarah Abdulla Molokhia · Iveena Delivery Systems, Inc. · R44 · FY2021 · EY
Retinal Gene Therapy
$909,201Zhijian Wu · National Eye Institute · ZIA · FY2014 · EY
Development of Sudaxine for the Treatment of Opioid Induced Respiratory Depression (OIRD) in the Peri-operative Hospital Setting
$908,519James N Bates · Atelerix Life Sciences Inc. · R44 · FY2022 · HL
MTR1: A Dinucleotide Substrate Enhancement and Molecular ByPass Therapy for Thymidine Kinase 2 Deficiency
$907,760Curtis Cui · Mitorainbow Therapeutics, Inc. · R44 · FY2022 · GM
Targeting Irritable Bowel Syndrome (IBS) with astressins
$906,525Dominic Behan · Sentia Medical Sciences, Inc. · R44 · FY2019 · DK
A Yeast-based Immunotherapy against Clostridioides difficile infection
$906,503Zhiyong Yang · Fzata, Inc. · R44 · FY2023 · AI
National Gene Vector Biorepository and Coordinating Center at Indiana University
$906,475Kenneth G Cornetta · Indiana University Indianapolis · P40 · FY2013 · HL
Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer
$905,526Stephen B Kahl · Manzanita Pharmaceuticals, Inc. · R44 · FY2024 · CA
Manganese Based MRI Contrast Agent - First In Human Clinical Trial
$903,512Vera Hoffman · Reveal Pharma · R44 · FY2022 · CA
National Gene Vector Biorepository and Coordinating Center at Indiana University
$903,034Kenneth G Cornetta · Indiana University Indianapolis · P40 · FY2012 · HL
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
$902,779D. Martin Watterson · Northwestern University At Chicago · U01 · FY2013 · AG
Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A
$901,762Gerald W. Dorn · Mitochondria In Motion, Inc. · R42 · FY2022 · NS
Resource Core
$901,640Shirish S Barve · Vanderbilt University Medical Center · P60 · FY2025 · AA
Development of a radiation-activatable nanoparticle for lung cancer therapy
$901,390Jin Xie · Athna Biotech, Inc. · R42 · FY2025 · CA
Protein therapeutic to facilitate healing of chronic wounds.
$898,170Tao Tan · Trim-Edicine, Inc. · R44 · FY2019 · GM